- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06505018
Plataforma de telemonitoramento "CUREETY TECHCARE" versus padrão de atendimento para pacientes mTBNC iniciando tratamento de primeira linha (ALTERNATIVE)
Um estudo randomizado de fase III comparando a plataforma de telemonitoramento digital "CUREETY TECHCARE" com o padrão usual de atendimento em pacientes com câncer de mama metastático triplo negativo iniciando um tratamento sistêmico de primeira linha
The goal of this clinical trial is to assess whether adding telemonitoring (the digital telemonitoring platform "CUREETY TECHCARE"), to standard care, will benefit patients with previously untreated metastatic triple-negative breast cancer starting first-line cancer therapy.
The main questions it aims to answer are:
- Is patient quality of life improved by using the telemonitoring platform?
- Are patients hospitalized less frequently when using the telemonitoring platform?
- Is the patient overall survival improved by telemonitoring ?
Researchers will compare data from patients using telemonitoring while receiving standard care with data from patients receiving only standard care.
Participants using telemonitoring will answer questions about their symptoms on the platform. The platform will analyze these symptoms, assess the patient's general condition and provide advice accordingly. Medical staff will also access the platform to monitor the patient's general condition and contact them if necessary.
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Arras, França
- Institut de Cancérologie des Hauts-de-France (ICHF)
-
Auxerre, França
- Centre Hospitalier d'Auxerre
-
Avignon, França
- Sainte Catherine - Institut du Cancer Avignon Provence
-
Bayeux, França
- CH Aunay-Bayeux
-
Beauvais, França
- Centre Hospitalier Simone Veil de Beauvais
-
Beuvry, França
- ICHF - Centre Pierre Curie
-
Blois, França
- Hôpital Simone Veil de Blois
-
Bordeaux, França
- Polyclinique bordeaux nord
-
Bourg-en-Bresse, França
- Centre Hospitalier Fleyriat
-
Caen, França
- Centre de Cancérologie Privé de Caen Maurice Tubiana
-
Caen, França
- Centre Francois Baclesse
-
Carcassonne, França
- Centre hospitalier de Carcasonne
-
Chambray-lès-Tours, França
- Recherche Oncologie Clinqiue 37 (ROC 37)
-
Cholet, França
- CH de Cholet
-
Colmar, França
- CH Colmar
-
Creil, França
- Groupe Hospitalier Public du Sud de l'Oise (GHPSO)
-
Dijon, França
- Centre Georges François Leclerc
-
Dunkirk, França
- Institut Andrée Dutreix
-
Fréjus, França
- Centre Hospitalier Intercommunal de Fréjus Saint Raphael
-
Grenoble, França
- Groupe Hospitalier Mutualiste de Grenoble
-
La Rochelle, França
- Groupe Hospitalier de La Rochelle-Ré-Aunis
-
La Réunion, França
- CHU de la réunion
-
La Réunion, França
- Clinique Sainte Clotilde
-
La Tronche, França
- CHU Grenoble Alpes
-
Le Coudray, França
- Centre Hospitalier Louis Pasteur
-
Le Mans, França
- Centre Hospitalier Le Mans
-
Le Puy-en-Velay, França
- Centre Hospitalier Emile Roux
-
Lorient, França
- GHBS Lorient
-
Lyon, França
- Clinique de la Sauvegarde
-
Lyon, França
- Centre Leon Berard
-
Lyon, França
- Hôpital Privé Jean Mermoz
-
Marseille, França
- Institut Paoli Calmettes
-
Mont-de-Marsan, França
- CHI de Mont-de-Marsan et du Pays des Sources
-
Montpellier, França
- Centre de Cancérologie du Grand Montpellier
-
Nantes, França
- Hôpital Privé du Confluent
-
Neuilly-sur-Seine, França
- Clinique Ambroise-Pare Hartmann
-
Neuilly-sur-Seine, França
- Hôpital Américain de PARIS
-
Nîmes, França
- CHU de Nimes
-
Orléans, França
- CHR Orleans
-
Osny, França
- CHP Sainte-Marie
-
Paris, França
- Diaconesses Croix Saint-Simon Hospital Complex
-
Pau, França
- Centre hospitalier de Pau
-
Plérin, França
- CARIO - Hopital Privé des Cotes d'Armor
-
Poitiers, França
- CHU de Poitiers
-
Reims, França
- Institut Godinot
-
Rouen, França
- Clinique Mathilde - Les Hôpitaux Privés Rouennais
-
Saint-Etienne, França
- CHU de Saint-Etienne
-
Saint-Mandé, França
- Hia Begin
-
Tours, França
- CHU de Tours
-
Vandœuvre-lès-Nancy, França
- Institut de Cancérologie de Lorraine
-
Épagny, França
- CH Annecy Genevois
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Signed a written informed consent form prior to participate in the study. Note: In case of physical incapacitation, a trusted representative of their choice, which is not the Investigator or sponsor, can sign on the behalf of the patients
- Patients ≥18 years of age.
- Patient with histologically documented metastatic triple negative breast cancer (ER (Oestrogen receptor) and PR (Progesterone receptor) <10%, Her2 negative status).
- Life expectancy > 6 months as per investigator estimate.
- Patient initiating a marketed authorized first-line systemic treatment in the metastatic setting.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2.
- Patient having completed the EORTC QLQ-C30 and EORTC QLQ-BR45 at baseline (response to questions 29 and 30 of EORTC QLQ-C30 at baseline are mandatory)
- Affiliated to the social security system or equivalent health insurance.
- Patient able and willing to complete web-based self-reported questionnaires, from initiation of first-line treatment and for the duration of the study (over multiple treatment lines)
- Patient has access to a computer, tablet, or smartphone connected to the Internet.
Exclusion Criteria:
- Participation in another clinical trial using telemonitoring.
- Physical or psychological incapacity of the patient to use the digital telemonitoring Cureety Techcare, according to the investigator's discretion.
- Patient deprived of their liberty or under protective custody or guardianship.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Sem intervenção: Grupo de atendimento padrão
|
|
|
Experimental: Telemonitoring group
Standard of care with digital telemonitoring "Cureety TechCare". The telemonitoring will comprise weekly adverse event (AE) evaluations and their analyses by the "Cureety TechCare". |
Each week, patients complete a questionnaire via the Cureety platform, specifically designed for the drug class or specific treatment being administered. Based on their responses, the Cureety TechCare algorithm classifies patients into one of four risk categories: "correct" (green), "compromised" (yellow), "state to be monitored" (orange), or "critical state" (red). (Note: the color code is not visible to the patient). The medical team uses the dashboard for daily patient monitoring and manages alerts related to the "clinical classification" of the patient's condition. The physician in charge of telemonitoring interprets the data, adjusts the treatment as needed, and provides supportive care during standard care consultations. Patients are also notified of alerts with tailored messages guiding them on the actions to take according to the category determined by the device. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to definitive Health-Related Quality of life score Deterioration
Prazo: At baseline then every 3 months, up to 24 months
|
The time to definitive Health-Related Quality of life score Deterioration is the length of time from randomization to the first deterioration of ≥ 10 points out of 100 or ≥2 points out of 14 in the global health status (GHS) score (items 29 and 30 of the QLQ-C30) compared with the baseline, assuming no improvement of at least 2 points in the GHS score compared with the baseline has occurred. The responses to the items 29-30 of the QLQ-C30 will be scored using the QLQ scoring manual. These 2 items have possible values ranging from 1 (very bad) to 7 (excellent) corresponding to a sum from 2 to 14 points. After conversion to percentages, the GHS will range from 0% to 100%. The higher the value, the better the quality of life. |
At baseline then every 3 months, up to 24 months
|
|
Hospitalization-free survival
Prazo: From randomization to death from any cause, up to 24 months
|
Hospitalization-free survival is the length of time from randomization during which patients enrolled in the study are not hospitalized and remain alive. |
From randomization to death from any cause, up to 24 months
|
|
Overall survival
Prazo: From randomization to death from any cause, up to 24 months after last inclusion
|
overall survival is the length of time from randomization during which patients enrolled in the study remain alive. |
From randomization to death from any cause, up to 24 months after last inclusion
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time-to-treatment failure
Prazo: From randomization to treatment discontinuation, up to 24 months
|
Time-to-treatment failure is the time interval (in months) between the initiation of first-line chemotherapy and its premature discontinuation, irrespective of the reason for discontinuation. |
From randomization to treatment discontinuation, up to 24 months
|
|
Toxicity-free survival
Prazo: From randomization until the first event, up to 24 months
|
The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the oncology research community as the leading rating scale for adverse events. This scale, divided into five grades (1 = "mild," 2 = "moderate," 3 = "severe," 4 = "life-threatening," and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders. Toxicity-free survival is defined as the time from randomization to the first event among a grade 3-4 non-hematological adverse event (graded using CTCAE version 5.0), a hospitalization for safety reasons, or death from any cause, whichever occurs first. |
From randomization until the first event, up to 24 months
|
|
Time to clinical deterioration
Prazo: From randomization, to the date of the first clinical deterioration, up to 24 months
|
-Time to clinical deterioration is defined by the time between randomization and deterioration of patient's level of functioning determined by the Eastern Cooperative Oncology Group (ECOG) performance status scale. The ECOG, widely accepted in the community of oncology research to assess how the disease affects the daily living abilities of the patient, is composed of 5 levels from grade 0 (fully active, able to carry on all pre-disease performance without restriction) to grade 5 (dead). |
From randomization, to the date of the first clinical deterioration, up to 24 months
|
|
Number of treatment lines
Prazo: Throughout study completion, up to 24 months
|
Number of successive treatment lines offered to the patient from randomization to the end of the study. |
Throughout study completion, up to 24 months
|
|
Incidence of Adverse Events
Prazo: Throughout study completion, up to 24 months
|
The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders. |
Throughout study completion, up to 24 months
|
|
Quality of life questionnaire - Core 30 (QLQ-C30)
Prazo: At baseline then every 3 weeks, up to 24 months
|
Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. |
At baseline then every 3 weeks, up to 24 months
|
|
Quality of Life Questionnaire - Breast cancer module (QLQ-BR45)
Prazo: At baseline then every 3 weeks, up to 24 months
|
This EORTC breast cancer specific questionnaire is intended to supplement the QLQ-C30. The QLQ-BR45 incorporates nine multi-item scales to assess body image, sexual functioning, breast satisfaction, systemic therapy side effects, arm symptoms, breast symptoms, endocrine therapy symptoms, skin mucosis symptoms, endocrine sexual symptoms. In addition, single items assess sexual enjoyment, future perspective and being upset by hair loss. All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale. Higher scores indicate more severe symptoms or problems for all items. |
At baseline then every 3 weeks, up to 24 months
|
|
Treatment compliance and extent of exposure
Prazo: Throughout study completion, up to 24 months
|
The treatment compliance and extent of exposure will be assess using dose intensity, treatment delays and dose reductions. |
Throughout study completion, up to 24 months
|
|
Compliance with the use of Cureety digital telemonitoring
Prazo: Throughout study completion, up to 24 months
|
Compliance is measured by the frequency of patient responses to the Cureety telemonitoring questionnaires. |
Throughout study completion, up to 24 months
|
|
Satisfaction with Cureety telemonitoring
Prazo: 3 months after randomisation for the patients and 1 year after the site activation for medical team
|
Satisfaction with Cureety telemonitoring is measured by the percentage of participants (patients and medical team [including nurse, clinical research associate, and investigators]) satisfied by the regular usage of the Cureety telemonitoring tool. |
3 months after randomisation for the patients and 1 year after the site activation for medical team
|
|
Patient's global satisfaction with care using the data of the EORTC OUT-PATSAT-35
Prazo: 6 months after randomisation
|
The OUT-PATSAT35 is a 35-item satisfaction with care questionnaire measuring cancer outpatients' perception of hospital doctors and nurses, as well as aspects of care organisation and services. Each item is rated from 1 to 5 (bad to excellent). |
6 months after randomisation
|
|
Socio-economic impact of digital telemonitoring
Prazo: Throughout study completion, up to 24 months after randomization
|
Socio-economic impact of digital telemonitoring will be assessed using the number of days of hospitalization and the number of unscheduled hospitalizations and emergency consultations |
Throughout study completion, up to 24 months after randomization
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jérôme MARTIN-BABAU, MD, Armorican Centre for Radiotherapy, Medical Imaging and Oncology, CARIO, Plérin
- Investigador principal: Florence JOLY, MD, François Baclesse Center, Caen
- Investigador principal: Frédéric FITENI, MD, University hospital of Nîmes
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- UC-BCG-2309
- IDRCB NUMBER: 2023-A02477-38 (Outro identificador: CPP Sud-Méditerranée III)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .